Roche Breast Cancer Drug Gets FDA Priority Review

Roche Holding AG Wednesday said the U.S. Food and Drug Administration has accepted the company's Biologics License Application for pertuzumab and granted Priority Review. MAIN FACTS: - The proposed indication is pertuzumab in combination with Herceptin (trastuzumab) and docetaxel chemotherapy for people with HER2-positive metastatic or locally recurrent, unresectable breast cancer, who have not received previous treatment or whose disease has relapsed after adjuvant therapy.

Back to news